Search - tctmd.com

April 15, 2021

News Daily News

New FDA Indication Opens Up Use of Sacubitril/Valsartan in HFpEF

February 16, 2021

News Daily News

Did Regional Differences Muddy Results in COMMANDER-HF?

February 04, 2021

News Opinion CV Team Dispatch

February 2021 News Roundup

February 01, 2021

News Conference News AHA 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

November 17, 2020

News Conference News AHA 2020

Empagliflozin Improves Cardiac Function, Exercise Capacity in Nondiabetic HFrEF

November 16, 2020

News Conference News HFSA 2020

EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

October 09, 2020

News Conference News ESC 2020

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

August 30, 2020

News Conference News ESC 2020

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

August 28, 2020

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

January 10, 2020

News Features

Year in Review: DAPA-HF Tops Heart Failure News Amid Other Wins and Losses

Shelley Wood

December 23, 2019

News Conference News AHA 2019

Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure

Shelley Wood

November 22, 2019

News Conference News AHA 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

November 17, 2019

News Daily News

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

October 21, 2019

News Conference News HFSA 2019

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

September 16, 2019

News Conference News ESC 2019

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

Yael L. Maxwell

September 12, 2019

$Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction Primary results of the PARAGON-HF trial$

Presentation ESC 2019

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Primary Results of the PARAGON-HF Trial

Presenter: Scott D. Solomon

September 01, 2019

News Conference News ESC 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

Shelley Wood

September 01, 2019

News Conference News ESC 2019

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

September 01, 2019

News Daily News

DAPA-HF: Dapagliflozin Scores a Win in Heart Failure